264 Development of allogeneic, potency-edited, anti-GPC3 CAR-T cells for the treatment of hepatocellular carcinoma

• Minh Pham,
• Dan li,
• Mitchell Ho,
• Dan Henderson,
• Jason Sagert

Affiliations

Minh Pham

1Crispr Therapeutics, Cambridge, MA, USA

Dan li

Department of Epidemiology, School of Public Health, Sun Yat-Sen University, Guangzhou, Guangdong, China

Mitchell Ho

2NIH, Bethesda, MD, USA

Dan Henderson

1Crispr Therapeutics, Cambridge, MA, USA

Jason Sagert

1Crispr Therapeutics, Cambridge, MA, USA